Result of AGM

Eden Research plc

29 September 2026

 

Eden Research plc

(“Eden” or “Company)

Result of AGM

Change of Name

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for global agriculture, announces that at the Annual General Meeting (“AGM”) held today, all resolutions were duly passed.

The total number of votes received by proxy on each resolution, as more fully disclosed in the Notice of AGM available on the Company's website, was as follows:

	Resolution	For	%	Against	%	Withheld
1	To lay the 2026 annual report	478,509,927	99.97	129,342	0.03	3,734,760
2	Re-appoint auditors	477,630,386	99.80	934,939	0.20	3,808,704
3	Re-elect Sean Smith	477,744,097	99.17	4,021,545	0.83	608,387
4	Re-elect Robin Cridland	453,000,434	99.12	4,021,751	0.88	25,351,844
5	Re-elect Lykele van der Broek	452,936,434	99.10	4,121,751	0.90	25,315,844
6	Re-elect Alex Abrey	477,844,097	99.17	4,021,545	0.83	508,387
7	Grant authority to the Directors to allot Ordinary Shares	455,790,434	94.50	26,502,049	5.50	81,546
8	Disapply statutory pre-emption rights on allotment of shares*	454,470,486	94.23	27,830,680	5.77	72,863
9	To approve the Remuneration Report	453,287,293	94.01	28,858,349	5.99	228,387
10	To approve the Remuneration Policy	452,945,940	93.94	29,199,702	6.06	228,387

Notes:

• * denotes Special Resolution.

• A vote Withheld is not a vote in law and is not counted in the calculation of the votes cast For or Against the resolution, nor in the calculation of the percentage of issued share capital voted for any resolution.
• Votes For and Against are expressed as a percentage of votes validly cast for that resolution by proxy, excluding any Withheld votes.

Change of Name

The Board has resolved, in accordance with the Company’s Articles, to change the Company’s name to Eden BioSolutions plc to better reflect its endeavours as a provider of solutions for the future of farming. The Company’s core focus is on developing and selling sustainable crop protection solutions for professional agriculture including fungicides, nematicides, seed treatments and insecticides.

The name change is expected to be confirmed shortly and in November 2026 the Company will provide an updated URL for its corporate website and AIM Rule 26 filings. A further announcement will be made once the name change is effective and the Registrar of Companies has issued a change of name certificate.

Investor presentation

A presentation delivered to shareholders at this morning’s AGM is available to view here:

https://www.edenresearch.com/investors/reports_and_presentations

Eden Research plc			www.edenresearch.com
Sean Smith, Chief Executive Officer			Via Walbrook PR
Alex Abrey, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated advisor and joint broker)				Tel: [phone]
Giles Balleny / Elysia Bough (Corporate Finance)
Harriet Ward (Corporate Broking) / Dale Bellis (Sales)
Oberon Capital (Joint Broker)			Tel: [phone]
Nick Lovering / Mike Seabrook / Adam Pollock
Walbrook PR (Media Relations & Investor Relations)		Tel: [phone] or [e-mail]
Paul McManus / Nick Rome / Anna Dunphy

Notes to Editors:

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.  It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

Cedroz™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally.  Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

Eden's seed treatment product (approval expected in 2026), Ecovelex was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, US and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

For more information about Eden, please visit:  www.edenresearch.com.

Follow Eden on LinkedIn, Twitter and YouTube. 

 

END